Breast
BGB-43395-101
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Breast cancer
Study Phase
Ia/Ib
Trial Identifiers
GenesisCare Location(s)
Principal Investigator(s)